We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer
Read MoreHide Full Article
Merck & Co., Inc. (MRK - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new label expansion of its blockbuster cancer drug, Keytruda in esophageal and gastroesophageal junction carcinoma.
The positive CHMP opinion is related to a marketing authorization application, seeking approval of the drug in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the esophagus or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal junction (GEJ) adenocarcinoma in patients whose tumors express PD-L1 (combined positive score ≥10). The European Commission will now review the CHMP’s recommendation and final decision on the label expansion is expected by the end of June.
Please note that a similar label expansion for Keytruda was approved by the FDA in March 2021.
The positive CHMP opinion and FDA approval was based on data from the phase III KEYNOTE-590 study, which evaluated Keytruda plus fluorouracil (“FU”) and cisplatin in the given patient population. Data from the same showed that treatment with the Keytruda combo led to significant improvement in overall survival, progression-free survival and objective response rate compared to FU and cisplatin alone, regardless of histology or PD-L1 expression status. The drug-chemotherapy regimen reduced the risk of death by 27% and reduced the risk of disease progression or death by 35%.
Shares of Merck have declined 3.4% so far this year against the industry’s increase of 7.4%.
We note that Keytruda is Merck’s major revenue-generating product. The drug recorded sales of almost $4 billion in the first quarter of 2021, up approximately 19% year over year.
Keytruda is continuously growing and expanding into new indications and markets, globally. In fact, the Keytruda development program is also progressing well as the drug is being studied for more than 30 types of cancer in more than 1450 studies, including several combination studies.
Merck has collaborated with several companies, including Amgen (AMGN - Free Report) , Glaxo (GSK - Free Report) and Pfizer (PFE - Free Report) , separately, for the evaluation of Keytruda in combination with other regimens.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency have sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
Image: Shutterstock
Merck (MRK) Gets CHMP Nod for Keytruda in Esophageal Cancer
Merck & Co., Inc. (MRK - Free Report) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new label expansion of its blockbuster cancer drug, Keytruda in esophageal and gastroesophageal junction carcinoma.
The positive CHMP opinion is related to a marketing authorization application, seeking approval of the drug in combination with platinum- and fluoropyrimidine-based chemotherapy for the first-line treatment of locally advanced unresectable or metastatic carcinoma of the esophagus or human epidermal growth factor receptor 2 (HER2)-negative gastroesophageal junction (GEJ) adenocarcinoma in patients whose tumors express PD-L1 (combined positive score ≥10). The European Commission will now review the CHMP’s recommendation and final decision on the label expansion is expected by the end of June.
Please note that a similar label expansion for Keytruda was approved by the FDA in March 2021.
The positive CHMP opinion and FDA approval was based on data from the phase III KEYNOTE-590 study, which evaluated Keytruda plus fluorouracil (“FU”) and cisplatin in the given patient population. Data from the same showed that treatment with the Keytruda combo led to significant improvement in overall survival, progression-free survival and objective response rate compared to FU and cisplatin alone, regardless of histology or PD-L1 expression status. The drug-chemotherapy regimen reduced the risk of death by 27% and reduced the risk of disease progression or death by 35%.
Shares of Merck have declined 3.4% so far this year against the industry’s increase of 7.4%.
We note that Keytruda is Merck’s major revenue-generating product. The drug recorded sales of almost $4 billion in the first quarter of 2021, up approximately 19% year over year.
Keytruda is continuously growing and expanding into new indications and markets, globally. In fact, the Keytruda development program is also progressing well as the drug is being studied for more than 30 types of cancer in more than 1450 studies, including several combination studies.
Merck has collaborated with several companies, including Amgen (AMGN - Free Report) , Glaxo (GSK - Free Report) and Pfizer (PFE - Free Report) , separately, for the evaluation of Keytruda in combination with other regimens.
Merck & Co., Inc. Price
Merck & Co., Inc. price | Merck & Co., Inc. Quote
Zacks Rank
Merck currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Bitcoin, Like the Internet Itself, Could Change Everything
Blockchain and cryptocurrency have sparked one of the most exciting discussion topics of a generation. Some call it the “Internet of Money” and predict it could change the way money works forever. If true, it could do to banks what Netflix did to Blockbuster and Amazon did to Sears. Experts agree we’re still in the early stages of this technology, and as it grows, it will create several investing opportunities.
Zacks has just revealed 3 companies that can help investors capitalize on the explosive profit potential of Bitcoin and the other cryptocurrencies with significantly less volatility than buying them directly.
See 3 crypto-related stocks now >>